A Leading Pharmaceutical Brand Increased Adherence 29% YoY with Swoop’s Patented Predictive Non-Adherence Audiences
With an increased incidence in substance use disorders (SUDs), a MAT therapy wanted to increase adherence within its patient population to drive positive patient outcomes. Leveraging Swoop’s patented predictive technology, the brand was able to accurately identify patients most likely to become non-adherent and activate them programmatically across premium inventory.
Help patients start and stay on therapy programs prescribed by their doctors
NimbleRx, a Swoop Company, connects prescription fulfillment capabilities with commercial intelligence to turn real-world signals into action, improve medication adherence, and reduce treatment delays.
Swoop earned the title of Best AI-Powered Health Solution for its Predictive Adherence Audiences and Best Health Equity or Accessibility Innovation for its en español patient Communities.
“Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy,” offers real-world insights into the treatment experience for MS patients.
A Patient Community Focused on Connecting People Living With a Rare Disease, myMDteam Provides Medically Reviewed Content, Support, and an Online Community
Swoop announces its acquisition of MyHealthTeam, the creator of one of the largest and most highly engaged opted-in patient social networks in the U.S.